Brussels (Belgium), February 19, 2009 - UCB announced today its plans to build a biologics pilot plant on its site of Braine-l’Alleud in Belgium, further executing its strategy to become the next generation biopharma leader focusing on central nervous system (CNS) and immunology.
“The intent to build a new pilot plant within UCB’s Braine-l’Alleud site is in line with UCB’s decision to focus on its core skills and adapt its competencies for the future, as outlined in the SHAPE programme’’, says Roch Doliveux, CEO of UCB.
This planned investment should amount to EUR 65 million and is supported by the Walloon Government. The biologics pilot plant is expected to become operational early 2012 and around 100 new job opportunities should be created in the medium-term. Advanced feasibility studies are currently ongoing.
The biologics pilot plant will allow UCB to further optimise the bio-manufacturing processes for its biological compounds under development, extending its knowledge and competencies in this field.
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 10 000 people in over 40 countries, UCB aims to achieve revenues of at least 3.3 billion euro in 2008. UCB is listed on Euronext Brussels (symbol: UCB).
Forward looking statement
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.
For the pdf version of this press release, please click on the link below: http://hugin.info/133973/R/1291915/292075.pdf
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved. Contact:
For further information:
Antje Witte Corporate Communications & Investor Relations, UCB T +32.2.559.9414 Email Contact
Nancy Nackaerts External Communications, UCB Mobile: +32 473 86 44 14 Email Contact
